Adam J. Moore

Adam J. Moore

Auto-generated profile, based on publicly available information

Adam J. Moore

Department of Epidemiology of Microbial Diseases, Yale School of Public Health

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Med
Verified
Journal Article
Closed access
CVChantal Vogels
Chantal Vogels
AWAnne E. Watkins
Anne E. Watkins
CHChristina A. Harden
Christina A. Harden
DBDouglas E. Brackney
Douglas E. Brackney
JSJared Shafer
Jared Shafer
NGNathan D. Grubaugh
Nathan D. Grubaugh

4 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
CVChantal Vogels
Chantal Vogels
AWAnne E. Watkins
Anne E. Watkins
CHChristina A. Harden
Christina A. Harden
DBDoug E. Brackney
Doug E. Brackney
JSJared Shafer
Jared Shafer
NGNathan D. Grubaugh
Nathan D. Grubaugh
Current bottlenecks for improving accessibility and scalability of SARS-CoV-2 testing include diagnostic assay costs, complexity, and supply chain shortages. To resolve these issues, we developed SalivaDirect, which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration on August 15th, 2020. The critical component of our approach is to use saliva instead of respiratory swabs, which enables non-invasive frequent sampling and reduces the need for trained healthcare professionals during collection. Furthermore, we simplified our diagnostic test by (1) not requiring nucleic acid preservatives at sample collection, (2) replacing nucleic acid extraction with a simple proteinase K and heat treatment step, and (3) testing specimens with a dualplex quantitative reverse transcription PCR (RT-qPCR) assay. We validated SalivaDirect with reagents and instruments from multiple vendors to minimize the risk for supply chain issues. Regardless of our tested combination of reagents and instruments from different vendors, we found that SalivaDirect is highly sensitive with a limit of detection of 6-12 SARS-CoV-2 copies/μL. When comparing SalivaDirect to paired nasopharyngeal swabs using the authorized ThermoFisher Scientific TaqPath COVID-19 combo kit, we found high agreement in testing outcomes (>94%). In partnership with the National Basketball Association (NBA) and Players Association, we conducted a large-scale (n = 3,779) SalivaDirect usability study and comparison to standard nasal/oral tests for asymptomatic and presymptomatic SARS-CoV-2 detection. From this cohort of healthy NBA players, staff, and contractors, we found that 99.7% of samples were valid using our saliva collection techniques and a 89.5% positive and >99.9% negative test agreement to swabs, demonstrating that saliva is a valid and noninvasive alternative to swabs for large-scale SARS-CoV-2 testing. SalivaDirect is a flexible and inexpensive ($1.21-$4.39/sample in reagent costs) option to help improve SARS-CoV-2 testing capacity. Register to become a designated laboratory to use SalivaDirect under our FDA EUA on our website: publichealth.yale.edu/salivadirect/.

8 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
YCYuping Cai
Yuping Cai
DKDaniel J. Kim
Daniel J. Kim
TTTakehiro Takahashi
Takehiro Takahashi
DBDavid I Broadhurst
David I Broadhurst
SMShuangge Ma
Shuangge Ma
Caroline JohnsonCaroline Johnson
Caroline Johnson
Coronavirus disease-2019 (COVID-19) has poorer clinical outcomes in males compared to females, and immune responses underlie these sex-related differences in disease trajectory. As immune responses are in part regulated by metabolites, we examined whether the serum metabolome has sex-specificity for immune responses in COVID-19. In males with COVID-19, kynurenic acid (KA) and a high KA to kynurenine (K) ratio was positively correlated with age, inflammatory cytokines, and chemokines and was negatively correlated with T cell responses, revealing that KA production is linked to immune responses in males. Males that clinically deteriorated had a higher KA:K ratio than those that stabilized. In females with COVID-19, this ratio positively correlated with T cell responses and did not correlate with age or clinical severity. KA is known to inhibit glutamate release, and we observed that serum glutamate is lower in patients that deteriorate from COVID-19 compared to those that stabilize, and correlates with immune responses. Analysis of Genotype-Tissue Expression (GTEx) data revealed that expression of kynurenine aminotransferase, which regulates KA production, correlates most strongly with cytokine levels and aryl hydrocarbon receptor activation in older males. This study reveals that KA has a sex-specific link to immune responses and clinical outcomes, in COVID-19 infection.

29 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MNMegha Nair
Megha Nair
GGGiselle Geering
Giselle Geering
AAAlyssa Agarwal
Alyssa Agarwal
RLRebecca Li
Rebecca Li
YQYujie Qiao
Yujie Qiao
ABAmy K. Bei
Amy K. Bei
Summary: RH5-Interacting Protein (RIPR) is essential for the invasion of Plasmodium into host red blood cells and is currently being studied as a novel malaria vaccine candidate in Phase 1a clinical trials. To study the genetic diversity of RIPR, deep amplicon sequencing was used to identify RIPR mutations in Plasmodium falciparum clinical isolates (n=89) collected in Kédougou, a high malaria transmission region of Senegal. We identified nonsynonymous single nucleotide polymorphisms (SNPs) in 64/89 (71.9%) of the samples. In total, 26 non-synonymous SNPs were identified, of which 15 were novel. 16/26 SNPs were able to be threaded onto existing RIPR crystal structures to predict the effects of SNPs on RIPR stability. 7/16 mutations were predicted to destabilize RIPR while 2/16 increased the stability of RIPR. Additionally, we identified 3 SNPs (Q737K, T738K, V840L) in the EGF5-8 domains of RIPR where neutralizing antibodies are known to bind.

16 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAdam J. Moore
Adam J. Moore
KRKoen K.A. Van Rompay
Koen K.A. Van Rompay
WLWilliam Louie
William Louie
JWJennifer K. Watanabe
Jennifer K. Watanabe
SASunny An
Sunny An
LCLark Coffey
Lark Coffey
Background: Mayaro virus (MAYV) is a mosquito-borne alphavirus endemic to Latin America that causes fever and arthritis. Unlike the related chikungunya virus, MAYV has not caused widespread, human-amplified epidemics. One possible explanation is that human viremia levels are too low to support transmission to urban Aedes ( Stegomyia ) aegypti mosquitoes. We used rhesus macaques (RM) to model human-to- Ae. aegypti transmission and to further expand understanding of their relevance to human MAYV disease. Methodology/Principal Findings: Twelve RM were inoculated with a genotype D lineage MAYV strain using one of 3 doses: 7 log 10 plaque forming units (PFU) intravenously (IV), 7 log 10 PFU subcutaneously (SC), or 3 log 10 PFU SC. Viremia was measured daily in plasma and RM were euthanized 10- or 12-days post-inoculation (dpi). On 2, 3, 5, and 7 dpi, Ae. aegypti were allowed to bloodfeed, incubated for 10 days, then dissected and tested to detect MAYV in tissues and saliva. RM developed infectious MAYV viremias lasting 3 days, peaking 1-2 dpi with titers ranging from 2-6 log 10 PFU/ml. RM inoculated with 7 log 10 PFU IV developed significantly higher viremias (area under the curve) than those receiving 3 log 10 PFU SC. MAYV RNA was detected in muscle, lymphoid, central nervous, and cardiac tissues. RM showed no signs of fever or joint swelling but some developed mild rashes in areas distant from mosquito feeding sites and histologic inflammation was observed in joints and muscles. Only Ae. aegypti that fed on viremic RM 2 dpi became infected, with an overall infection rate of 48%. Among all mosquitoes that fed on RM 2 dpi, only 2% (4/217) had infectious MAYV in their saliva, suggesting transmission competence. Despite 11 of 12 RM transmitting MAYV to at least one mosquito, individual RM varied in infectiousness to Ae. aegypti, and mosquito cohort infection rates did not correlate with RM viremia levels. Conclusions/Significance: RM exhibit short-lived MAYV viremias, broad tissue tropism, and mild joint and muscle inflammation, closely resembling human infection. While viremic RM can infect Ae. aegypti , the transmission window is narrow and transmission by Ae. aegypti is rare. The combination of a short infectious period in RM and low transmissibility of Ae. aegypti infected from RM may help explain the absence of widespread urban MAYV outbreaks. AUTHOR SUMMARY: Mayaro virus (MAYV) is a mosquito-borne virus found in Latin America that causes fever and joint pain, similar to chikungunya virus (CHIKV). However, unlike CHIKV, MAYV has not led to large outbreaks. One reason may be that levels of MAYV in human blood are too low for Aedes aegypti mosquitoes—known for spreading chikungunya, dengue, and Zika—to pick up and transmit the virus in cities. To better understand this, we studied rhesus macaques, a monkey species that serves as a model for how MAYV behaves in people. We tracked virus levels in their blood and tissues and observed mild joint and muscle inflammation, similar to Mayaro fever in people. Although the macaques were able to infect some Ae. aegypti mosquitoes, the transmission window was short, and only a few mosquitoes that became infected had virus in their saliva, suggesting transmission competence. This limited ability of urban mosquitoes to spread MAYV may help explain why major outbreaks have not occurred.

14 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ABAboubacar Ba
Aboubacar Ba
LTLaty Gaye Thiam
Laty Gaye Thiam
MPMariama Nicole Pouye
Mariama Nicole Pouye
YGYicheng Guo
Yicheng Guo
SPSaurabh D. Patel
Saurabh D. Patel
ABAmy K. Bei
Amy K. Bei
The Plasmodium falciparum cysteine-rich protective antigen (PfCyRPA) is a promising target as a next-generation blood-stage malaria vaccine and together with PCRCR complex members, the reticulocyte binding-like homologous protein 5 (PfRh5) and the Rh5-interacting protein (PfRipr), are currently being evaluated in clinical trials. PfCyRPA is essential for merozoite invasion and appears to be highly conserved within the P. falciparum parasite populations. Here, we used a targeted deep amplicon next-generation sequencing approach to assess the breadth of PfCyRPA genetic diversity in 95 P. falciparum clinical isolates from Kédougou, an area with a high seasonal malaria transmission in Senegal. Our data show the dominant prevalence of PfCyRPA wild type reference allele, while we also identify a total of 15 single nucleotide polymorphisms (SNPs). Of these, only five have previously been reported, while the majority of the SNPs were present as singletons within our sampled population. Moreover, the variant read frequency of the identified SNPs varied from 2.6 to 100%, while the majority of the SNPs were present at frequencies greater than 25% in polygenomic samples. We also applied a structure-based modelling approach to thread these SNPs onto PfCyRPA crystal structures and showed that these polymorphisms have different predicted functional impacts on the interactions with binding partner PfRH5 or neutralizing antibodies. Our prediction revealed that the majority of these SNPs have minor effects on PfCyRPA antibodies, while others alter its structure, stability, or interaction with PfRH5. Altogether, our present findings reveal conserved PfCyRPA epitopes which will inform downstream investigations on next-generation structure-guided malaria vaccine design.